The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, John Barrett, Renier J Brentjens, Jill Brufsky, Jorge Cortes, Marcos De Lima, Stephen J Forman, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, Jeffrey S Miller, John M PagelSee the full list of authors
19 October 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaNina Shah, Jack Aiello, David E Avigan, Jesus G Berdeja, Ivan M Borrello, Ajai Chari, Adam D Cohen, Karthik Ganapathi, Lissa Gray, Damian Green, Amrita Krishnan, Yi Lin, Elisabet Manasanch, Nikhil C Munshi, Ajay K NookaSee the full list of authors
12 July 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspectiveCasey Quinn, Louis P Garrison, Anja K Pownell, Michael B Atkins, Gérard de Pouvourville, Kevin Harrington, Paolo Antonio Ascierto, Phil McEwan, Samuel Wagner, John Borrill, Elise Wu
12 July 2020
Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and managementJarushka Naidoo, Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Patrick M Forde, Seema Mehta Steinke, Clare Rock, Douglas B Johnson, Mizuki Nishino, Julie R Brahmer
17 June 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationJanis M Taube, Guray Akturk, Michael Angelo, Elizabeth L Engle, Sacha Gnjatic, Shirley Greenbaum, Noah F Greenwald, Cyrus V Hedvat, Travis J Hollmann, Jonathan Juco, Edwin R Parra, Marlon C Rebelatto, David L Rimm, Jaime Rodriguez-Canales, Kurt A SchalperSee the full list of authors
15 May 2020
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseFernanda I Arnaldez, Steven J O'Day, Charles G Drake, Bernard A Fox, Bingqing Fu, Walter J Urba, Vincenzo Montesarchio, Jeffrey S Weber, Haiming Wei, Jon M Wigginton, Paolo Antonio Ascierto
7 May 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M. Kluger, Hussein A. Tawbi, Maria L. Ascierto, Michaela Bowden, Margaret K. Callahan, Edward Cha, Helen X. Chen, Charles G. Drake, David M. Feltquate, Robert L. Ferris, James L. Gulley, Shilpa Gupta, Rachel W. Humphrey, Theresa M. LaVallee, Dung T. LeSee the full list of authors
1 April 2020
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality SummitSara Pai, David Blaisdell, Rachel Brodie, Robert Carlson, Heidi Finnes, Michele Galioto, Roxanne E Jensen, Tom Valuck, Antonia R Sepulveda, Howard L Kaufman
16 January 2020
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. VossSee the full list of authors
20 December 2019
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Ezra E. W. Cohen, R. Bryan Bell, Carlo B. Bifulco, Barbara Burtness, Maura L. Gillison, Kevin J. Harrington, Quynh-Thu Le, Nancy Y. Lee, Rom Leidner, Rebecca L. Lewis, Lisa Licitra, Hisham Mehanna, Loren K. Mell, Adam Raben, Andrew G. SikoraSee the full list of authors
15 July 2019
